Africa: Covid-19 – Local Researchers Welcome Sputnik V Vaccine Findings

Local researchers have welcomed findings for Russia’s Sputnik V viral vector vaccine, which achieved efficacy of 91.6% in preventing symptomatic COVID-19 in a large Phase 3 clinical trial. They say it is a boost to global efforts to control the pandemic.

The findings from a preliminary analysis of the Phase 3 clinical trial were published in The Lancet medical journal on Tuesday. Unlike most other Phase 3 COVID-19 vaccine trials, the vaccine and control groups in this trial were not the same size, but split in a three to one ratio.

The analysis based on data from nearly 20 000 participants showed that the two-shot vaccine offered full protection from severe disease. There were no serious adverse events associated with the vaccine and it was found to be safe and effective in people over 60 years of age, who are at highest risk for severe disease and death.

The preliminary results do not show whether Sputnik V reduces the risk of transmission or asymptomatic infection, and it is not clear how long protection lasts.

The trial is ongoing and aiming to include 40 000 people. Monitoring of safety and efficacy is continuing.

Confirmation of Sputnik V’s efficacy and safety is easing scientific scepticism of the Gamaleya Institute’s vaccine after it was given state approval in August before Phase 3 testing. There were concerns at the time that Russia’s premature regulatory approval of the vaccine was driven by geopolitical ambitions.

Sputnik V has been given regulatory approval in 16 countries so far, including Hungary, which broke ranks with the European Union last month by becoming the first bloc member to approve it. The latest data has been submitted to the European regulator for review.

‘Rigorous and positive’

Africa Health Research Institute (AHRI) Director and vaccinology expert Professor Willem Hanekom says the results are “rigorous and positive and contribute to the field” of COVID-19 vaccine development.

He said the lack of diversity – only white males were included in the study and no mention of the vaccine’s efficacy on HIV – is notable. “But, there is a good spread across ages” from 18 to over 60 years of age.

Professor Linda-Gail Bekker, the Director of the Desmond Tutu HIV Centre and co-leader of the ENSEMBLE Johnson and Johnson trial in South Africa says the Sputnik trial is “compelling” but she, like Hanekom, questions the absence of data for HIV-positive people. She says more research is needed to find out whether the vaccine is safe and effective for people living with HIV.

Similar to the Oxford/AstraZeneca vaccine, Sputnik V is a viral vector vaccine which is based on a modified version of adenovirus, a common cold virus. This is tailored to carry genetic instructions for making the coronavirus spike protein, which it passes to human cells. The manufactured coronavirus spike protein then triggers an immune response to protect against COVID-19.

Sputnik V, however, uses a different human adenovirus for each of the two doses – initially recombinant human adenovirus Type 26 (rAd26-S) followed by a booster shot with Type 5 (rAd5-S) to trigger a stronger immune response and reduce the risk of resistance. AstraZeneca uses a double dose of Type 26 and Johnson & Johnson, a single dose of Type 26.

The Johnson and Johnson vaccine also uses the Type 26 in a single dose. “The only question I have around the Type 5 boost, is that the data we have from previous HIV trials using the Ad5 platform was not successful and worryingly, in certain populations, we saw an increased risk of acquiring HIV,” Bekker says.

Another high efficacy vaccine

A round-up of the current vaccine front runners puts The Gamaleya Research Institute’s Sputnik V vaccine in the same high efficacy group as the mRNA vaccines made by Moderna and Pfizer-BioNtech which show efficacy of around 95%. It is important to note that, while efficacy in preventing COVID-19 varies between the six current vaccines, they all appear to be highly effective at preventing severe COVID-19 and death.

Efficacy rates for the Oxford University/AstraZeneca vaccine have varied between 62% to 90% in late clinical trials, with most trial results in the lower end of that range. One million doses of the Covishield vaccine manufactured by the Serum Institute of India, under licence from AstraZeneca, was the first vaccine to reach South Africa’s shores. The two dose vaccine will initially be rolled out to health care workers.

Preliminary findings, not yet published in a reputable medical journal, for the single dose Johnson & Johnson vaccine in Phase 3 clinical trials, show 66% efficacy overall, with 72% in the United States, 57% in South Africa, where the highly transmissible 501Y.V2 variant is dominant. The vaccine showed 85% efficacy at preventing moderate-to-severe disease 28 days after vaccination. Over 40 000 participants were enrolled.

Novavax recently announced its vaccine was 89% effective in its United Kingdom Phase 3 trial. The South African phase 2b trial of the vaccine suggests 60% efficacy against mild and severe COVID-19 among the 94% of trial participants living without HIV. The overall efficacy in South Africa of 49% included HIV-positive volunteers, but the numbers were low, which makes these numbers highly uncertain. The researchers say the highly contagious 501Y.V2 variant was responsible for 90% of infections in the South African arm of the study, which enrolled 4 400 volunteers.

‘Phenomenal protection against severe disease’

Hanekom says that crucial results showing that the vaccines used in all these trials prevent severe disease and death is being lost, even though it means a heavy weight will be lifted off overburdened hospitals and health workers if people are given these vaccines.

“We want vaccines to protect individuals, but we also know we’re going to control the epidemic with more than 50% efficacy. While the higher efficacy vaccines prevent severe disease and death, the Johnson and Johnson, Novavax and AstraZeneca vaccines, with lower efficacy rates, have also shown phenomenal protection against severe disease and death. And, for me, that is by far the most important thing for an individual,” says Hanekom.

Bekker agrees. “If everyone is vaccinated, we know we have a reduced risk of death and severe disease. We need to get away from the idea that we are going to stop infection in everyone 100 percent… we need to calculate how we think about this and get back to a reasonable goal of normality. It’s encouraging that although we (Johnson and Johnson) took a hit for efficacy overall we are the same globally for reduction of death and disease.”

Variant uncertainties

The emergence of the 501Y.V2 variant in South Africa has shown a deft ability to dodge protective antibodies in the bloodstream. Vaccines developed before the emergence of the variant in South Africa have shown reduced ability to protect against the variant.